Silence Therapeutics

Silence Therapeutics is a clinical-stage biotechnology company developing siRNA therapeutics using its proprietary platform.

The platform enables precise silencing of disease-associated genes expressed in the liver, without permanently altering DNA.

Its pipeline addresses cardiovascular disease, haematological conditions, and rare diseases, with programmes licensed to major pharmaceutical partners.

The company also partners with pharma companies seeking to access siRNA technology for their own discovery pipelines.